Pieris Pharmaceuticals, Inc. (PIRS) financial statements (2020 and earlier)

Company profile

Business Address 255 STATE STREET
BOSTON, MA 02109
State of Incorp. NV
Fiscal Year End December 31
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
6/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments104128732929180
Cash and cash equivalents6275382929180
Short-term investments425335    
Receivables73160 0 
Prepaid expense     0 
Deferred costs13 1 2 
Other current assets     1 
Other undisclosed current assets31222(2) 
Total current assets:115135903332200
Noncurrent Assets
Property, plant and equipment2054222 
Long-term investments and receivables  10    
Long-term investments  10    
Other noncurrent assets31000  
Other undisclosed noncurrent assets3    0 
Total noncurrent assets:26614222 
TOTAL ASSETS:1411411043534220
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities161296320
Accounts payable6322110
Accrued liabilities1096421 
Employee-related liabilities     0 
Debt     1 
Deferred revenue and credits36372   
Deferred tax liabilities    0 
Contract with customer, liability11 
Other liabilities     0 
Other undisclosed current liabilities     (0) 
Total current liabilities:2748468340
Noncurrent Liabilities
Liabilities, other than long-term debt4753471010
Deferred revenue and credits53471   
Accounts payable and accrued liabilities    00 
Contract with customer, liability47 
Accrued environmental loss contingencies     0 
Estimated litigation liability     0 
Due to related parties      0
Other liabilities 000   
Other undisclosed noncurrent liabilities15    (0) 
Total noncurrent liabilities:6353471000
Total liabilities:901019210340
Stockholders' equity
Stockholders' equity attributable to parent, including:5140122531180
Preferred stock   0   
Common stock0000000
Additional paid in capital227190136129112850
Accumulated other comprehensive loss(2)(3)(5)(2)(1)(1) 
Accumulated deficit(174)(147)(120)(103)(80)(66)(0)
Other undisclosed stockholders' equity attributable to parent     (0) 
Total stockholders' equity:5140122531180
TOTAL LIABILITIES AND EQUITY:1411411043534220

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
6/30/2014
Revenue, net2711301 
Gross profit:462925635 
Operating expenses(73)(60)(40)(29)(17)(13)(0)
Other undisclosed operating income     0 
Operating loss:(27)(31)(15)(23)(14)(7)(0)
Nonoperating income (expense)03(2)00(3) 
Investment income, nonoperating 2     
Foreign currency transaction gain (loss), before tax0(0)(0)    
Debt instrument, convertible, beneficial conversion feature     2 
Other nonoperating income (expense)(0)2(2)000 
Interest and debt expense     (3) 
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes2000(0)  
Loss from continuing operations before equity method investments, income taxes:(25)(27)(17)(23)(14)(13)(0)
Other undisclosed income from continuing operations before income taxes   0 3 
Loss from continuing operations before income taxes:(25)(27)(17)(23)(14)(10)(0)
Income tax expense (benefit) 0(1)(0)(0)0 
Net loss attributable to parent:(25)(27)(18)(23)(14)(10)(0)
Other undisclosed net loss available to common stockholders, basic(3)      
Net loss available to common stockholders, diluted:(28)(27)(18)(23)(14)(10)(0)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
6/30/2014
Net loss:(25)(27)(18)(23)(14)(10)(0)
Other comprehensive loss (0)     
Comprehensive loss:(25)(27)(18)(23)(14)(10)(0)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent12(3)(0)(0)0 
Comprehensive loss, net of tax, attributable to parent:(24)(25)(21)(23)(14)(10)(0)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: